On March 18, 2026, a new bill was introduced in the Maryland legislature focused on enhancing transparency within the pharmaceutical sector.
The legislation requires drug manufacturers and patient advocacy groups to reveal their connections to disease awareness initiatives.
This move is intended to bolster trust in these campaigns and ensure that stakeholders are aware of potential conflicts of interest.